Patents by Inventor Michael C. Jensen

Michael C. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160333377
    Abstract: Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9-mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.
    Type: Application
    Filed: May 12, 2016
    Publication date: November 17, 2016
    Inventors: Andrew Scharenberg, David Rawlings, Michael C. Jensen, Kamila Gwiazda, Alexandra Grier
  • Publication number: 20160175398
    Abstract: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 23, 2016
    Inventor: Michael C. Jensen
  • Publication number: 20150306141
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Application
    Filed: August 20, 2013
    Publication date: October 29, 2015
    Inventors: Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
  • Publication number: 20150297640
    Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.
    Type: Application
    Filed: November 17, 2014
    Publication date: October 22, 2015
    Inventors: Laurence Cooper, Michael C. Jensen
  • Publication number: 20140356398
    Abstract: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Application
    Filed: June 12, 2014
    Publication date: December 4, 2014
    Inventors: Stanley R. Riddell, Carolina Berger, Michael C. Jensen
  • Patent number: 8802374
    Abstract: A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 12, 2014
    Assignee: City of Hope
    Inventor: Michael C. Jensen
  • Patent number: 8329882
    Abstract: The present application relates to nucleic acids that encode a RNA switch responsive to a ligand that can control the expression of a gene product that affects the cell fate determination of a mammalian cell are provided. In some embodiments, the system can be used to control the proliferation or activation of mammalian cells in response to a ligand that can be provided exogenously to the mammalian cell or can be produced by the mammalian cell. The system can be used to promote the growth or proliferation of human T cells in response to an exogenous ligand applied to the cells. In one embodiment, the system detects the ligand through a RNA aptamer that modulates expression of a gene product through activation or inactivation of a ribozyme that modulates expression of the gene product.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: December 11, 2012
    Assignees: California Institute of Technology, City of Hope
    Inventors: Christina D. Smolke, Yvonne Y. Chen, Michael C. Jensen
  • Publication number: 20120301447
    Abstract: A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways.
    Type: Application
    Filed: May 3, 2012
    Publication date: November 29, 2012
    Inventor: Michael C. Jensen
  • Publication number: 20100226901
    Abstract: The present application relates to nucleic acids that encode a RNA switch responsive to a ligand that can control the expression of a gene product that affects the cell fate determination of a mammalian cell are provided. In some embodiments, the system can be used to control the proliferation or activation of mammalian cells in response to a ligand that can be provided exogenously to the mammalian cell or can be produced by the mammalian cell. The system can be used to promote the growth or proliferation of human T cells in response to an exogenous ligand applied to the cells. In one embodiment, the system detects the ligand through a RNA aptamer that modulates expression of a gene product through activation or inactivation of a ribozyme that modulates expression of the gene product.
    Type: Application
    Filed: February 18, 2010
    Publication date: September 9, 2010
    Applicants: CALIFORINA INSTITUTE OF TECHNOLOGY, CITY OF HOPE
    Inventors: CHRISTINE D. SMOLKE, YVONNE Y. CHEN, MICHAEL C. JENSEN
  • Publication number: 20090324630
    Abstract: Novel recombinant vectors encoding viral antigens within a single vector or construct are disclosed. The vectors may be used to initiate immunological responses to antigens and to combat opportunistic and other infections. Viral antigens include those derived from CMV, EBV, adenovirus (Ad), Influenza A, herpes simplex, varicella, polyoma virus and respiratory viruses. A recombinant vector or construct may encode two antigenic peptides, three antigenic peptides (“TriVi”), or more than three antigenic peptides. Methods of making and other methods of using the novel recombinant vectors or constructs are also disclosed.
    Type: Application
    Filed: April 21, 2009
    Publication date: December 31, 2009
    Inventor: Michael C. Jensen
  • Publication number: 20080131415
    Abstract: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Application
    Filed: October 11, 2007
    Publication date: June 5, 2008
    Inventors: Stanley R. Riddell, Carolina Berger, Michael C. Jensen
  • Publication number: 20040126363
    Abstract: Genetically engineered, CD19-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CD19, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD19+ malignancies and for abrogating any untoward B cell function. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain scFvFc:&zgr; receptor where scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and &zgr; represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain &zgr; are linked by a transmembrane domain such as the transmembrane domain of CD4. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
    Type: Application
    Filed: May 7, 2003
    Publication date: July 1, 2004
    Inventors: Michael C. Jensen, Stephen Forman, Andrew Raubitschek
  • Publication number: 20030166201
    Abstract: Compositions and methods for use in generating and selecting genetically modified cells are provided. The compositions include selectable markers and selection systems based thereon. Also provided are methods for the introduction and expression of heterologous nucleic acids in host animals that use the compositions and methods for generating and selecting genetically modified cells.
    Type: Application
    Filed: April 30, 2001
    Publication date: September 4, 2003
    Inventor: Michael C. Jensen
  • Patent number: 6410319
    Abstract: Genetically engineered, CD20-specific redirected T cells expressing a cell surface protein-having an extracellular domain comprising a receptor which is specific for CD20, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD20+ malignancies and for abrogating any untoward B cell function. In one embodiment, the cell surface protein is a single chain FvFc:&zgr; receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CD20 linked by peptide, Fc represents a hinge-CH2-CH3 region of a human IgG1, and &zgr; represents the intracellular signaling domain of the zeta chain of human CD3. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: June 25, 2002
    Assignee: City of Hope
    Inventors: Andrew Raubitschek, Anna Wu, Michael C. Jensen